Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Otsuka Holdings Co ( (JP:4578) ) just unveiled an announcement.
Otsuka Holdings Co., Ltd. announced that its subsidiary, Taiho Pharmaceutical, will acquire Swiss biotech company Araris Biotech AG for $400 million, with potential additional milestone payments of up to $740 million. This acquisition will enhance Taiho’s capabilities in developing next-generation ADCs, strengthening its oncology portfolio and positioning it as a leader in innovative cancer therapies.
More about Otsuka Holdings Co
Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, primarily focusing on oncology and immune-related diseases through its subsidiary, Taiho Pharmaceutical. Taiho is known for developing small-molecule oral therapeutic drugs and is expanding into biologics with a focus on antibody-drug conjugates (ADCs).
YTD Price Performance: -13.10%
Average Trading Volume: 693
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $27.51B
For a thorough assessment of 4578 stock, go to TipRanks’ Stock Analysis page.